LAG3
ENSG00000089692
Target class
Unclassified protein
Chromosome
12
Approved drugs
1
Clinical candidates (approved and in development)
6
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- CD223
- Target name
- LAG3
- Gene name
- Lymphocyte activating 3
- Gene symbol
- LAG3
- Protein name
- Lymphocyte activation gene 3 protein (LAG-3) (CD antigen CD223) [Cleaved into: Secreted lymphocyte activation gene 3 protein (sLAG-3)]
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Immunoglobulin like domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 36
- Highest tissue expression
- 39.92
- Tissue specificity (Gini)
- 0.654
- Tissue specificity (tau)
- 0.907
- KEGG gene identifiers
- hsa:3902
- Reactome pathways
- R-HSA-2132295
- Protein interaction confidence
- 0.82405
- Protein interaction partners
- 60
- End position
- 6778455
- Start position
- 6772360
- Chromosome
- 12
- Strand
- Forward
- [Lymphocyte activation gene 3 protein]: Cell membrane
- Single-pass type I membrane protein . Note=Clusters on the T-cell surface following ligand-binding. .
- SUBCELLULAR LOCATION: [Secreted lymphocyte activation gene 3 protein]: Secreted . Note=Produced following cleavage of the main chain. .
- PubMed 1380059
- PubMed 1692078
- PubMed 35761082
- PubMed 9634475
- Tissue specificity (tau)
- 0.907092
- Expression inequality (Gini)
- 0.653565
Expression in transcripts per million
- Ovary
- 39.92
- Spleen
- 28.08
- Cells - EBV-transformed lymphocytes
- 20.16
- Uterus
- 18.08
- Small Intestine - Terminal Ileum
- 10.36
Expression in transcripts per million
- Ovary39.92
- Spleen28.08
- Cells - EBV-transformed lymphocytes20.16
- Uterus18.08
- Small Intestine - Terminal Ileum10.36
- Fallopian Tube8.86
- Cervix - Endocervix8.57
- Colon - Sigmoid8.28
- Testis7.06
- Vagina6.11
- Prostate5.89
- Lung5.71
- Nerve - Tibial5.62
- Esophagus - Muscularis5.09
- Colon - Transverse4.86
- Cervix - Ectocervix4.82
- Esophagus - Gastroesophageal Junction4.09
- Adipose - Visceral (Omentum)3.66
- Whole Blood3.29
- Bladder3.21
- Liver2.71
- Brain - Cerebellum2.35
- Stomach2.13
- Kidney - Medulla2.1
- Brain - Cerebellar Hemisphere1.99
And 29 more, listed on the interactive page.
- GO:0002841
- GO:0050860
- GO:0050868
Cellular components
- GO:0005886
- GO:0003823
- GO:0004888
- GO:0005515
- GO:0042289
Related records
Trials (175)
- A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
- A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
- A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
- A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
- A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
- A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
- A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
- A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
- A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Drugs (6)
- Eftilagimod alfa Lymphocyte activation gene 3 protein vaccine antigen
- Favezelimab Lymphocyte activation gene 3 protein inhibitor
- Fianlimab Lymphocyte activation gene 3 protein inhibitor
- Ieramilimab Lymphocyte activation gene 3 protein inhibitor
- Relatlimab Lymphocyte activation gene 3 protein inhibitor
- Tebotelimab Lymphocyte activation gene 3 protein inhibitor